Evidence map›Paper›PMID 36001141›Full record

ArticleJournal of neurology2022

Atypical Alzheimer's disease phenotypes with normal or borderline PET biomarker profiles.

Neha Atulkumar Singh, Jonathan Graff-Radford, Mary M Machulda, Christopher G Schwarz, Matthew C Baker, Rosa Rademakers, Nilufer Ertekin-Taner, Val J Lowe, Keith A Josephs, Jennifer L Whitwell

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Review
  4. AβJournal of Alzheimer's disease : JAD · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Neha Atulkumar SinghDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Christopher G SchwarzDepartment of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
Matthew C BakerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Rosa RademakersDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Nilufer Ertekin-TanerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. whitwell.jennifer@mayo.edu.ORCID http://orcid.org/0000-0001-6914-1563
Mayo Clinic · USMayo Clinic in Arizona · USMayo Clinic in Florida · US

Funding

Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal studyR01AG050603 · NIA · MAYO CLINIC ROCHESTER · PI WHITWELL, JENNIFER LOUISE · 2016 to 2025
$5.9M
Alzheimer's Association NIRG-12-242215NIA NIH HHS R01 AG050603NIH HHS R01-AG50603
6 · The paper itself

Abstract

Posterior cortical atrophy (PCA) and logopenic progressive aphasia (LPA) are clinical syndromes that commonly have underlying Alzheimer's disease (AD), although non-AD pathologies have also been reported. PET imaging allows for identification of beta-amyloid (Aβ) and tau in AD, so we aimed to assess these in a large cohort to identify patients that do not have evidence for biomarker-defined AD. Eight-one patients, 47 PCA and 34 LPA, underwent extensive neurological and neuropsychological testing, [

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersHumansPhenotypePositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAbnormal Aβ-PET uptakeAbnormal tau-PET uptakeLogopenic progressive aphasiaPosterior cortical atrophy

Identifiers

PMID36001141
PMCPMC9707302
OpenAlexW4292883076

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.